Cargando…

Comorbidities in multiple sclerosis—a plea for interdisciplinary collaboration to improve the quality of life of MS patients

The negative influence of comorbidities on the quality of life of people with multiple sclerosis is evident and the problem is increasingly acknowledged by numerous international studies in long-term care. One therapeutic option would be an add-on therapy with vitamin D (VD), with the aim of achievi...

Descripción completa

Detalles Bibliográficos
Autor principal: Goischke, Hans-Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584285/
https://www.ncbi.nlm.nih.gov/pubmed/31354380
http://dx.doi.org/10.2147/DNND.S204555
_version_ 1783428494082965504
author Goischke, Hans-Klaus
author_facet Goischke, Hans-Klaus
author_sort Goischke, Hans-Klaus
collection PubMed
description The negative influence of comorbidities on the quality of life of people with multiple sclerosis is evident and the problem is increasingly acknowledged by numerous international studies in long-term care. One therapeutic option would be an add-on therapy with vitamin D (VD), with the aim of achieving a therapeutically effective dose. The individually required VD dose must be tested, since the response to a certain dose is subject to variations between individuals. A possible toxicity with increased 1.25(OH)D3 (active VD metabolite) is largely prevented by increased activity of 24-hydroxylase (CYP24A1). Monitoring of serum VD levels as well as serum calcium and phosphate levels (optional Ca excretion in 24-hour urine, Ca creatinine ratio in urine) provides safety and is necessary because possible mutations on the (catabolic) CYP24A1 gene can lead to a partial or total loss of 24-hydroxylase activity and provoke hypercalcemia/hyperphosphatemia. The main therapeutic objective is to maintain functional and social independence by using drugs with a high safety profile. The prevention and optimal management of comorbidities can influence the quality of life of patients with MS (PwMS) when included in patient care. Adequate measures can reduce the burden of MS only if the risk of comorbidity is reduced through targeted monitoring, early detection and diagnosis. Such a strategy will contribute to influencing the premature mortality of patients with MS. If VD is recognized as a “multipurpose steroid hormone”, it could also be used to maintain cognitive function and prevent premature possible dementia, especially as there is evidence that VD deficiency correlates with brain atrophy (hippocampus). At present, MS therapy is still a balancing act between therapeutically efficient action and the management of unexpected side effects, with VD add-on therapy being almost unproblematic and most likely to be accepted by PwMS.
format Online
Article
Text
id pubmed-6584285
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65842852019-07-26 Comorbidities in multiple sclerosis—a plea for interdisciplinary collaboration to improve the quality of life of MS patients Goischke, Hans-Klaus Degener Neurol Neuromuscul Dis Review The negative influence of comorbidities on the quality of life of people with multiple sclerosis is evident and the problem is increasingly acknowledged by numerous international studies in long-term care. One therapeutic option would be an add-on therapy with vitamin D (VD), with the aim of achieving a therapeutically effective dose. The individually required VD dose must be tested, since the response to a certain dose is subject to variations between individuals. A possible toxicity with increased 1.25(OH)D3 (active VD metabolite) is largely prevented by increased activity of 24-hydroxylase (CYP24A1). Monitoring of serum VD levels as well as serum calcium and phosphate levels (optional Ca excretion in 24-hour urine, Ca creatinine ratio in urine) provides safety and is necessary because possible mutations on the (catabolic) CYP24A1 gene can lead to a partial or total loss of 24-hydroxylase activity and provoke hypercalcemia/hyperphosphatemia. The main therapeutic objective is to maintain functional and social independence by using drugs with a high safety profile. The prevention and optimal management of comorbidities can influence the quality of life of patients with MS (PwMS) when included in patient care. Adequate measures can reduce the burden of MS only if the risk of comorbidity is reduced through targeted monitoring, early detection and diagnosis. Such a strategy will contribute to influencing the premature mortality of patients with MS. If VD is recognized as a “multipurpose steroid hormone”, it could also be used to maintain cognitive function and prevent premature possible dementia, especially as there is evidence that VD deficiency correlates with brain atrophy (hippocampus). At present, MS therapy is still a balancing act between therapeutically efficient action and the management of unexpected side effects, with VD add-on therapy being almost unproblematic and most likely to be accepted by PwMS. Dove 2019-06-13 /pmc/articles/PMC6584285/ /pubmed/31354380 http://dx.doi.org/10.2147/DNND.S204555 Text en © 2019 Goischke. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Goischke, Hans-Klaus
Comorbidities in multiple sclerosis—a plea for interdisciplinary collaboration to improve the quality of life of MS patients
title Comorbidities in multiple sclerosis—a plea for interdisciplinary collaboration to improve the quality of life of MS patients
title_full Comorbidities in multiple sclerosis—a plea for interdisciplinary collaboration to improve the quality of life of MS patients
title_fullStr Comorbidities in multiple sclerosis—a plea for interdisciplinary collaboration to improve the quality of life of MS patients
title_full_unstemmed Comorbidities in multiple sclerosis—a plea for interdisciplinary collaboration to improve the quality of life of MS patients
title_short Comorbidities in multiple sclerosis—a plea for interdisciplinary collaboration to improve the quality of life of MS patients
title_sort comorbidities in multiple sclerosis—a plea for interdisciplinary collaboration to improve the quality of life of ms patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584285/
https://www.ncbi.nlm.nih.gov/pubmed/31354380
http://dx.doi.org/10.2147/DNND.S204555
work_keys_str_mv AT goischkehansklaus comorbiditiesinmultiplesclerosisapleaforinterdisciplinarycollaborationtoimprovethequalityoflifeofmspatients